Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 39, Issue 4, Pages 975-985Publisher
WILEY
DOI: 10.1002/eji.200839167
Keywords
Clinical trial; DNA-MVA vaccines; HIV-1; Memory T cells
Categories
Funding
- Medical Research Council UK
- Jenner Institute Investigator
- Medical Research Council [MC_U137884179] Funding Source: researchfish
- MRC [MC_U137884179] Funding Source: UKRI
Ask authors/readers for more resources
Induction of a long-term immunological memory, which can expand and defend the host upon pathogen encounter, is the holy grail of vaccinology. Here, using a sensitive cultured IFN-gamma ELISPOT assay, we show that 50% (15 out of 30) of healthy, HIV-1/2-uninfected volunteers who received pTHr.HIVA DNA prime-modified vaccinia virus Ankara. HIVA boost vaccine regimen 1 to 3 1/2 years ago had detectable HIV-1-specific T-cell responses. These T cells, predominantly of the CD4(+) subtype, could proliferate and produce multiple cytokines in response to in vitro peptide stimulation. Peptide mapping studies showed that the vaccine-induced CD4(+) T cells were mostly directed toward epitopes targeted in HIV-1-infected individuals. In addition, we used the same assay to re-evaluate 51 volunteers from past vaccine trial IAVI-006 and corrected the previously reported 10% of vaccine responders to 50%. Thus, we confirmed that cultured assays are a valuable tool for studying T-cell memory. These results are discussed in the context of the current state-of-affairs of the HIV-1 vaccine field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available